Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lactobacillus Plantarum (Cect7484 And Cect7485)
Therapeutic Area : Neurology
Study Phase : Undisclosed
Recipient : Scripps Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of a Multispecies Probiotic on Migraine
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 06, 2021
Lead Product(s) : Lactobacillus Plantarum (Cect7484 And Cect7485)
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Recipient : Scripps Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mermed One
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Recipient : University of Nottingham
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparison of an Alginate Containing Enteral Feed and an Alginate Free Enteral Feed.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
October 02, 2019
Lead Product(s) : Mermed One
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Recipient : University of Nottingham
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coenzyme Q10
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Recipient : Beth Israel Deaconess Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Ubiquinol as a Metabolic Resuscitator in Post-Cardiac Arrest
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
October 17, 2016
Lead Product(s) : Coenzyme Q10
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Recipient : Beth Israel Deaconess Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coenzyme Q10
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Recipient : Massachusetts General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Assessing Bioavailability of CoQ10 Supplementation in Burn Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
September 29, 2014
Lead Product(s) : Coenzyme Q10
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Recipient : Massachusetts General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chrysanthemum Flower Oil
Therapeutic Area : Rheumatology
Study Phase : Undisclosed
Recipient : Hiroshima University
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Chrysanthemum Flower Oil and Its Dose-dependency on Hyperuricemia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
August 11, 2014
Lead Product(s) : Chrysanthemum Flower Oil
Therapeutic Area : Rheumatology
Highest Development Status : Undisclosed
Recipient : Hiroshima University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coenzyme Q10
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : Beth Israel Deaconess Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Ubiquinol (Reduced COQ10) for Patients With Sepsis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
September 23, 2013
Lead Product(s) : Coenzyme Q10
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : Beth Israel Deaconess Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
